A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.

Anne M. Noonan,Maryam B. Lustberg,Patrick Schnell,John L. Hays,Ning Jin,Laith I. Abushahin,Pannaga G. Malalur,Sameek Roychowdhury,Rifat T. Elkhatib,Hui-Zi Chen,Salwan S. Al Mutar,Alex Sparreboom,Shuiying Hu

A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.

2020

Anne M. Noonan
Maryam B. Lustberg
Patrick Schnell
John L. Hays
Ning Jin
Laith I. Abushahin
Pannaga G. Malalur
Sameek Roychowdhury
Rifat T. Elkhatib
Hui-Zi Chen
Salwan S. Al Mutar
Alex Sparreboom
Shuiying Hu

TPS12125Background: Neurotoxicity is one of the most significant and disabling side effects of oxaliplatin and frequently limits the cumulative amount that can be used. The mechanism of oxaliplatin...

Keywords:

Colorectal cancer
Bevacizumab
Oncology
FOLFOX
Internal medicine
Chemotherapy
Pathology
Oxaliplatin
in patient
Dasatinib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations